PLUS THERAPEUTICS, Inc.

Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Good afternoon ladies and gentlemen. Welcome to the Plus Therapeutics third quarter 2020 earning results call. At this time all participants have been placed in a listen only mode and the floor will open for your questions following the presentation. If you would like to ask a question at that time, please press star 1 on your touch tone phone. If at any point your question has been answered, you may remove yourself from the queue by pressing the pound key. We ask that you please pick up your handset to allow optimal sound quality. If you should require operator assistance, please press star 0. And before we begin, we want to advise you that over the course of this call and question and answer session, Foreworking statements will be made regarding events, trends, business prospects, and financial performance which may affect PLUS Therapeutics' future operating results and financial position. All such statements are subject to risk and uncertainties, including the risk and uncertainties described under the risk factor section included in PLUS Therapeutics' annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commissions from time to time. PLUS Therapeutics advises you to review these risk factors in considering such statements. PLUS Therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made. It is now my pleasure to turn the floor over to Dr. Mark Hedrick, PLUS Therapeutics President and Chief Executive Officer. Sir, you may begin.

Thank you, Kathryn. Good afternoon, and thank you for taking the time to join us today. as we provide a business update and discuss our 2020 third quarter results. Joining me on the call today is Mr. Andrew Sims, our Chief Financial Officer. Before Andrew provides financial performance, .

. And second, an update on additional potential target clinical indications .